Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro An...
FDA Device Recall #Z-0318-2026 - Class I, August 28, 2025
Recall Summary
| Recall Number | Z-0318-2026 |
| Classification | Class I - Serious risk |
| Date Initiated | August 28, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Dexcom, Inc. |
| Location | San Diego, CA |
| Product Type | Devices |
| Quantity | 333 |
Product Description
Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro Android US CGM App Model/Catalog Number: SW11678 Software Version: version 1.15.0 Product Description: Dexcom G6 and G6 Pro Android US CGM App SW11678 version 1.15.0 Component: Dexcom G6 Continuous Glucose Monitoring System
Reason for Recall
A software defect in version v1.15.0 of the G6 Android app can cause the app to terminate unexpectedly, which may result in the user not receiving estimated glucose values, alarms, alerts or notifications. This could result in the missed detection of a hyperglycemic or hypoglycemic event, protentional resulting in severe hyperglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS).
Distribution Pattern
This product was distributed throughout the US. G6 Android US v1.15.0 SW11678 G6 and G6 Pro Android app release has been halted <1% rollout after this issue was identified. Please see the attached consignee data for additional details.
Lot / Code Information
Lot Code: UDI: SW11678 - 00386270000811
Other Recalls from Dexcom, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2574-2026 | Class II | Brand Name: Dexcom G7 Continuous Glucose Monito... | May 27, 2026 |
| Z-2165-2026 | Class II | Brand Name: Dexcom ONE+ Continuous Glucose Moni... | Apr 14, 2026 |
| Z-2163-2026 | Class II | Brand Name: Dexcom G7 Continuous Glucose Monito... | Apr 14, 2026 |
| Z-2164-2026 | Class II | Brand Name: Dexcom G7 Continuous Glucose Monito... | Apr 14, 2026 |
| Z-2447-2025 | Class I | Brand Name: Dexcom G7 Continuous Glucose Monito... | Jul 24, 2025 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.